Ally Bridge Group’s Edgewise Therapeutics EWTX Stock Holding History

Ally Bridge Group’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.38M	Sell	83,300 -77,700	-48%	-$2.68M	2.99%	9
2026 Q1	$5.07M	Sell	161,000 -34,000	-17%	-$980K	4.1%	11
2025 Q4	$4.84M	Buy	+195,000	New	+$3.91M	5.04%	10
2025 Q2	–	Sell	-102,650	Closed	-$2.26M	–	32
2025 Q1	$2.26M	Buy	102,650 +19,474	+23%	+$511K	2.04%	20
2024 Q4	$2.22M	Sell	83,176 -104,519	-56%	-$3.33M	1.9%	26
2024 Q3	$5.01M	Buy	+187,695	New	+$3.73M	2.68%	18

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ally Bridge Group's EWTX Position: Q2 2026 in Review

Ally Bridge Group reduced its Edgewise Therapeutics (EWTX) stake by 48% in Q2 2026, selling an estimated $2.68M and leaving 83,300 shares worth $3.38M. The position accounts for 2.99% of the portfolio, ranked #9.

Ally Bridge Group first reported a position in EWTX in Q3 2024 and has held it in 6 quarters since. The position peaked at $5.07M in Q1 2026. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

Ally Bridge Group held 83,300 shares of Edgewise Therapeutics worth $3.38M as of Q2 2026.
Ally Bridge Group sold 77,700 Edgewise Therapeutics shares in Q2 2026, an estimated $2.68M.
Edgewise Therapeutics made up 2.99% of Ally Bridge Group's portfolio in Q2 2026, its #9 holding.
Ally Bridge Group first reported a position in Edgewise Therapeutics in Q3 2024 and has held it in 6 quarters since.
Ally Bridge Group's Edgewise Therapeutics position peaked at $5.07M in Q1 2026.
226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Ally Bridge Group's 13F filing for Q2 2026, filed 14 Aug 2026.